Delivery Order SPE2DB25D3007-SPE2DB25FWSWH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls, a pharmaceutical product for treating autoimmune conditions. The contract, awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. Performance will be executed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,610.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL on September 17, 2025, with an ultimate completion date of September 18, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product for immune-mediated conditions. Awarded on August 10, 2025, with an ultimate completion date of August 11, 2025, this firm fixed price delivery order represents a competitive award with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $19,051.96 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. The award, issued on July 14, 2025, with an ultimate completion date of July 15, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used in the treatment of inflammatory conditions. This firm fixed-price delivery order, valued at $11,878.23, represents a non-competitive set-aside award and is scheduled for completion by September 16, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product for treating inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,265.90 delivery order on July 18, 2025, for HUMIRA (CF) Pen 40 mg/0.4 mls, with completion scheduled for July 21, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This competitively awarded, non-set-aside delivery order carries a firm fixed price ceiling value of $7,652.27 and is scheduled for completion by September 16, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $2,719.71 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of HUMIRA (CF) Pen 40 MG/0.4 MLS, a pharmaceutical product for treating autoimmune conditions. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September...
- The Defense Logistics Agency awarded a delivery order valued at $1,394.58 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used to treat inflammatory conditions. The contract was awarded on August 19, 2025, with a completion date of August 20, 2025, and employs firm fixed price pricing with no set-aside designation. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- SPE2DB25D3007Indefinite Delivery Contract
- SPE2DB25D3007-SPE2DB25FWSWHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,129.13 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a prescription pharmaceutical product used to treat inflammatory conditions. This firm fixed-price delivery order, awarded on September 15, 2025, is set to conclude on September 16, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a competitive award with no set-aside designation. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp supplies brand-name and generic medications, vaccines, and specialized healthcare commodities to support military and veteran healthcare systems. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to fulfill federal medical supply requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 9/15/25 |